Gastroenterology

Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease




CT-P13 is equivalent to reference product in primary outcome; no difference in safety outcomes

Source link




Related posts

YAP1-induced MALAT1 promotes epithelial–mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer

Newsemia

Geriatric IBD mortality trend highlights need for ‘more standardized guidelines’

Newsemia

Doppler Probe Use Is Cost Effective in Nonvariceal Upper GI Bleeding

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy